![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rani Therapeutics Holdings Inc | NASDAQ:RANI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.08 | 2.70 | 4.90 | 0 | 09:08:42 |
The first of Rani’s abstracts noted below will be featured in a news conference hosted by the Endocrine Society from 9-10 am C.T. on June 17, 2023 in Room W-186B in McCormick Place’s West Building.
Details of the abstracts being presented at ENDO are as follows:
Abstract Title: An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers the Human Parathyroid Hormone Analog hPTH (1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 StudySession Title: P69 - Bone and Mineral Metabolism: HypoparathyroidismSession Type: Poster Abstract Date & Time: Saturday June 17, 2023, 1:00-2:00 pm C.T.Location: McCormick Place, EXPO HallPresenter: Joshua Myers, MSNominated for Presidential Poster Competition: Endocrine Society to select winnerSelected for Rapid Fire Presentation: Quick preview poster presentation on a multimedia display to allow meeting attendees to further engage with the presenters at their paper poster. Rapid Fire presentations will take place in the Poster Pod area in the exhibit hall. News Feature: This abstract will be featured in a news conference hosted by the Endocrine Society.
Abstract Title: Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102)Session Title: P69 - Bone and Mineral Metabolism: HypoparathyroidismSession Type: Poster AbstractDate & Time: Saturday June 17, 2023, 1:00-2:00 pm C.T.Location: McCormick Place, EXPO HallPresenter: Kyle Horlen, DVMNominated for Presidential Poster Competition: Endocrine Society to select winner
Abstract Title: Patient Preference and Proof-of-Concept for a Once-Daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered via an Orally Ingestible Robotic Pill (RT-112)Session Title: Session P44 - Reproductive Endocrinology: Female Reproduction – ClinicalSession Type: Poster AbstractDate & Time: Friday, June 16, 2023, 12:00-1:00 pm C.T. Location: McCormick Place, EXPO HallPresenter: Alyson Yamaguchi, DVM
Information about ENDO 2023 may be accessed at https://endo2023.endocrine.org/Home.
About Rani Therapeutics
Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
1 Year Rani Therapeutics Chart |
1 Month Rani Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions